While the medication does not directly cause gastrointestinal bleeding, its effects on bowel function may indirectly contribute to conditions like hemorrhoids or anal fissures that produce rectal bleeding
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
The medications they provide contain the same active ingredients as brand-name products
Instead, in the present study, we focused on food preoccupation, reflecting a conceptual shift that dysregulated eating behaviors are a result of disruption in both hedonic and homeostatic processes (for more information, see Methods) 1,4,11
Never use external heat sources like hot water or heating pads, as extreme temperature can damage the medication
